Efficacy and safety of topical 2% dorzolamide and 0.5% timolol in cases of open angle glaucoma in a tertiary care hospital of East Singhbhum: an observational, prospective and comparative study

Akash Chandra; Manish Kumar; Amrendra Narayan Mishra

doi:10.18203/2319-2003.ijbcp20182673

Authors

Akash Chandra Department of Pharmacology, IGIMS, Patna, Bihar, India
Manish Kumar Department of Pharmacology, IGIMS, Patna, Bihar, India
Amrendra Narayan Mishra Department of Pharmacology, MGM Medical College & Hospital, Jamshedpur, Jharkhand, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20182673

Keywords:

Intraocular pressure, Topical 2% dorzolamide, Topical 0.5% timolol, Primary open angle glaucoma

Abstract

Background: Present study was undertaken to evaluate and compare the efficacy and side effects of 2% dorzolamide and 0.5% timolol in patients with open angle glaucoma.

Methods: There were 60 randomly selected patients were equally divided into Group I (n=30) and Group II (n=30). Further both groups were divided into IA (n=10), IB (n=20), IIA (n=10) and IIB (n=20). 2% Dorzolamide hydrochloride in Group IA and IIA and 0.5% Timolol maleate in Group IB and IIB was administered for 24 weeks. Patients were evaluated for general and ocular examinations on day of enrolment and then at the end of 1st, 4th, 8th and 24th week. Adverse effects of the drug during study period were also noted. Mean±SD, t value, p value and comparison between groups were analysed by graph pad software.

Results: At the end of 24 weeks difference in mean reduction of IOP was not significant with 6.2±1.85mm Hg (Right eye) and 5.55±1.68mm Hg (left eye) and 4.72±2.97mm Hg (Right eye) and 5.37±1.24mm Hg (left eye) in Group IA and Group IIA respectively. At the end of 24 weeks difference in mean reduction of IOP was not significant with 5.06±1.62mm Hg (Right eye) and 4.40±1.96mm Hg (left eye) and 4.30±1.41mm Hg (Right eye) and 4.12±2.08mm Hg (left eye) in Group IB and Group IIB respectively. Fall in both systolic and diastolic blood pressure in both the groups were significant. Both drug regimens were well-tolerated, and no serious drug-related adverse effects were reported.

Conclusions: Dorzolamide was more efficacious for reduction of intra ocular pressure, well-tolerated, had low allergic response and had a favourable ocular, cardiovascular and respiratory safety profile than Timolol.

Metrics

Metrics Loading ...

References

Weinreb RN, Aung T, Medeiros FA. The Pathophysiology and Treatment of Glaucoma: A Review. JAMA. 2014 May 14;311(18):1901-11.

Mishima S, Masuda K, Tamura T. Chapter 4. Drugs Influencing Aqueous Humor Formation and Drainage. Dikstein S (ed): Drugs and Ocular Tissues. 2nd Meeting of the International Society for Eye Research, Jerusalem, September 1976: Proceedings. Basel, Karger, 1977:128-287.

Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous Humor Dynamics: A Review. Open Ophthalmol J. September 2010;4:52-9.

Thomas R, Loibl K, Parikh R. Evaluation of a glaucoma patient. Indian J Ophthalmol. 2011 Jan;59(1):S43-52.

Smith SD, Singh K, Lin SC, Chen PP, Chen TC, Francis BA, et al. Evaluation of the Anterior Chamber Angle in Glaucoma. A Report by the American Academy of Ophthalmology. Ophthalmology, Volume 120, Number 10, October 2013:1985-1997.

Bunga T. A clinical study on management of primary open angle glaucoma. Inte J of Inf Res and Revie. 2015;2(2):416-9.

Katz IM, Hubbard WA, Getson AJ, Gould AL. Intraocular pressure decreases in normal volunteers following timolol ophthalmic solution. Investigative Ophthalmology and Visual Science. June 1976;15:489-92.

Radius RL, Diamond GR, Pollack IP, Langham ME. Tirnolol A new Drug for management of chronic simple glaucoma Arch. Ophthal. (Chicago). 1978;96:1003-8.

Hoste AM. Beta-Blockers. In Tarek Shaarawy, Mark B. Sherwood, Roger A. Hitchings and Jonathan G. Crowston editors. Glaucoma (2nd Edition). 2015;1:548-558 (Available online 2 September 2014).

Rosenberg LF, Krupin T, Tang LQ, Hong PH, Ruderman JM. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 1998 Jan;105(1):88-93.

Balfour JA, Wilde MI. Dorzolamide. A Review of its Pharmacology and Therapeutic Potential in the Management of Glaucoma and Ocular Hypertension. Drugs and Aging. May 1997;10(5):384-403.

Scardillo A, Pugliese M, De Majo M, Niutta PP, Pugliese A. Effects of Topical 0.5% Levobunolol Alone or in Association With 2% Dorzolamide Compared with a Fixed Combination of 0.5% Timolol and 2% Dorzolamide on Intraocular Pressure and Heart Rate in Dogs Without Glaucoma. Veterinary Therapeutics. 2010;11(3):E1-E6.

Hamed AA, M. Salem HA, Haikal MA. Apraclonidine versus Timolol eye drops of management of Open-angle glaucoma. Bull. Ophthalmol Soc. Eqypt. 1997;90(2):243-6.

Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clinical therapeutics. 2000 Jan; 22(1):103-11.

Derick RJ, Robin AL, Waltersb TR, Barnebey HS, Choplin N, Schuman J, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. January 1997;104(1):131-6.

Strahlman E, Tipping R, Vogel R. A Double-Masked, Randomized 1-Year Study Comparing Dorzolamide (Trusopt), Timolol, and Betaxolol. Arch Ophthalmol. 1995;113(8):1009-16.